The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region:  its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.

doi:10.1097/FPC.0b013e32835d9b0b

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.

Pharmacogenetics and genomics - 1 Mar 2013

Sebio Ana, Paré Laia, Páez David, Salazar Juliana, González Alan, Sala Núria, del Río Elisabeth, Martín-Richard Marta, Tobeña María, Barnadas Agustí, Baiget Montserrat

Abstract excerpt

OBJECTIVE: Although KRAS mutation status has been identified as a strong predictor of response to anti-epidermal growth factor receptor (EGFR) therapies, not all wild-type patients respond. The lethal-7 (let-7) family of microRNAs regulates KRAS activity. A functional polymorphism (rs61764370) has been described in the let-7 complementary site (LCS6). We hypothesized a possible association between this KRAS let-7...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3' Untranslated Regions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Binding Sites

Share to Colorectal Neoplasms

Share to ErbB Receptors

Share to KRAS gene

Share to Genes, ras

Share to Neoplasm Metastasis

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed

Identifiers

PMID: 23324806
DOI: 10.1097/FPC.0b013e32835d9b0b

Genes

KRAS
EGFR
BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.PMID 23324806Read ↗

Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.Semantic proximity Read ↗

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.Semantic proximity Read ↗

High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.Semantic proximity Read ↗

Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.Semantic proximity Read ↗

A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.Semantic proximity Read ↗

Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).Semantic proximity Read ↗

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.Semantic proximity Read ↗

Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patientsSemantic proximity Read ↗

Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.Semantic proximity Read ↗

The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis.Semantic proximity Read ↗

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).Semantic proximity Read ↗

KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.